MEDX:NSD-Horizon Kinetics Medical ETF (USD)

ETF | Others |

Last Closing

USD 30.56

Change

-0.03 (-0.11)%

Market Cap

N/A

Volume

117.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
QQQM Invesco NASDAQ 100 ETF

+0.53 (+0.26%)

USD 33.55B
QQQM Invesco NASDAQ 100 ETF

+0.53 (+0.26%)

USD 33.55B
ACWI iShares MSCI ACWI ETF

-0.01 (-0.01%)

USD 19.10B
ACWI iShares MSCI ACWI ETF

-0.01 (-0.01%)

USD 19.10B
IBIT iShares Bitcoin Trust

-1.26 (-3.37%)

USD 17.74B
IBIT iShares Bitcoin Trust

-1.26 (-3.37%)

USD 17.74B
JEPQ JPMorgan Nasdaq Equity Premium..

+0.13 (+0.24%)

USD 16.68B
JEPQ JPMorgan Nasdaq Equity Premium..

+0.13 (+0.24%)

USD 16.68B
CGABL The Carlyle Group Inc. 4.625% ..

-0.37 (-1.86%)

USD 16.14B
CGABL The Carlyle Group Inc. 4.625% ..

-0.37 (-1.86%)

USD 16.14B

ETFs Containing MEDX

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.42% 64% D 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.42% 61% D- 63% D
Trailing 12 Months  
Capital Gain 5.93% 43% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.93% 37% F 48% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.41% N/A N/A 44% F
Dividend Return 0.41% N/A N/A 40% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1.33% N/A N/A 100% F
Risk Adjusted Return 30.71% N/A N/A 63% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector